Telix Pharmaceuticals Secures $105M in Funding, Raises 2023 Guidance to $60M

Telix Pharmaceuticals Ltd. investors are suing the company for allegedly overstating its progress in prostate cancer therapeutic candidates and misrepresenting its supply chain and partners. The lawsuit seeks damages under federal securities laws. To join the class action, visit https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. at 866-767-3653. A lead plaintiff must move the court by January 9, 2026.